Residual platelet reactivity with aspirin therapy in acute coronary syndrome and chronic phases of coronary artery disease: comparison between whole blood aggregometry and a point-of-care method

• Grant number: 10/17916-0
• Support Opportunities: Scholarships in Brazil - Scientific Initiation
• Start date: January 01, 2011
• End date: December 31, 2011
• Field of knowledge: Health Sciences - Medicine - Medical Clinics
• Principal Investigator: José Carlos Nicolau
• Grantee: Amanda Lettieri Monteiro
• Host Institution: Instituto do Coração Professor Euryclides de Jesus Zerbini (INCOR). Hospital das Clínicas da Faculdade de Medicina da USP (HCFMUSP). Secretaria da Saúde (São Paulo - Estado). São Paulo , SP, Brazil

Abstract

Aspirin makes up the first-line treatment for patients with coronary artery disease. Nevertheless, some recent studies have suggested that the response to regular use of aspirin is not uniform in patients with chronic coronary artery disease, and still little studied in the setting of acute coronary syndromes. However, the lack of standardization and variability of platelet aggregation tests used to measure response to aspirin did not allow a definitive conclusion on the subject. The main objective of this analysis is to evaluate the correlation between two methods of platelet aggregation widespread in medical practice, whole blood aggregometry and Verify-Now. This will included 50 patients with acute coronary syndromes without ST-segment elevation on previous use of AAS for analyzes of platelet aggregation within 48 hours of onset and three months later. The present analysis will be linked to the study "inadequate response to aspirin in coronary disease: comparison between acute and chronic phases.